GlassScriptPhysician profile
Susan D Delman
NPI 1427261510
$1,547.92
in general payments reported to CMS, 2019-2025
23 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $109 · 2022: $18.54 · 2023: $239 · 2024: $325 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.87 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $201.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $170.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Integra Lifesciences Corporation | $112.29 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $87.23 | 2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $73.87 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Organogenesis INC. | $72.67 | 2019 | |
| Pfizer INC. | $71.54 | 2020-2025 | |
| Amgen INC. | $68.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $45.19 | 2024-2025 | |
| Exact Sciences Corporation | $42.95 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $39.92 | 2022-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $36.59 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $35.59 | 2019-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.43 | 2024 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $26.07 | 2019-2025 | Zoryve |
| Dexcom, INC. | $25.82 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $18.84 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.61 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.22 | 2025 | Xifaxan |
| Allergan, INC. | $13.74 | 2019 | |
| Amarin Pharma, INC. | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Delman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.